Elastic Stockings for VTE Prevention – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Lara N. Roberts and Emma Gee, adding:
“Elastic stockings for VTE prevention: is it time to let them go?
Antiembolism stockings (AES) have been a cornerstone of VTE prevention for decades.
But a new editorial by Lara Roberts and Emma Gee in RPTH Journal makes a compelling case that the evidence no longer supports their routine use, and that the time for deimplementation has come.
What the evidence shows:
- The CLOTS1 trial in stroke patients: no meaningful reduction in VTE, but a 5% risk of skin damage (OR 4.2)
- The GAPS trial: adding AES to LMWH was no better than LMWH alone in surgical patients (absolute risk difference 0.3%)
- A meta-analysis confirmed no reduction in DVT, PE, or VTE mortality with AES added to pharmacologic prophylaxis
- Correct application of AES is suboptimal in trials (15–31%) and even worse in the real world (60% incorrect use)
- Skin damage including blisters, ulcers, and necrosis occurs in 3–5% of patients
Beyond clinical harm:
- AES use costs an estimated £63 million annually in England for surgical patients alone, including nursing time, procurement, and supply chain
- Made from non-recyclable synthetic materials, AES contribute to healthcare’s environmental footprint
With earlier mobilisation and shorter hospital stays now standard, the clinical context in which AES were originally shown to work has largely disappeared.
The authors call for a planned, systems-level deimplementation strategy, supported by staff education, updated guidelines, and post-implementation surveillance.
A bold but evidence-based position worth reading.”
Title: Elastic stockings for venous thromboembolism prevention, time to go
Authors: Lara N. Roberts, Emma Gee
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?
-
Nov 15, 2026, 15:25Hussnain Javaid: Thalassaemia 2026 New Therapies Transforming UK Practice